Anti-HER2/neu TCR-T Cells in Action: linking transcriptional signatures, secretomics, and In Vivo tumor suppression
These findings validate the broader utility of the previously identified HER2/neu-specific TCR repertoire and elucidate the molecular mechanisms driving its therapeutic efficacy, demonstrating the potential of TCR-T cells for treating solid tumors through robust cytotoxic activity and the emergence of a favorable CD4+CD8+ T cell population. This study offers critical mechanistic insights, establishing a foundation for advancing TCR-engineered therapies toward clinical use in HER2/neu-positive cancers.
Authors
- Roman Perik-Zavodskii (ORCID: https://orcid.org/0000-0002-5055-4859)
- E. L. Zavjalov (ORCID: https://orcid.org/0000-0002-9412-3874)
- Saleh Alrhmoun (ORCID: https://orcid.org/0000-0003-0788-5385)
- Kirill Nazarov (ORCID: https://orcid.org/0000-0001-7175-4051)
- Elena Golikova
- M.S. Fisher (ORCID: https://orcid.org/0000-0001-6261-7557)
- Julia Shevchenko (ORCID: https://orcid.org/0000-0001-8773-0599)
- V.V. Kurilin (ORCID: https://orcid.org/0000-0002-5617-0450)
- Olga Perik-Zavodskaia (ORCID: https://orcid.org/0000-0003-4911-1994)
- С. В. Сенников (ORCID: https://orcid.org/0000-0002-7366-7768)
- Julia Lopatnikova (ORCID: https://orcid.org/0000-0003-0089-5054)
- Petr Glybochko (ORCID: https://orcid.org/0000-0002-5541-2251)
- Peter S. Timashev (ORCID: https://orcid.org/0000-0001-7773-2435)
- Julia Philippova (ORCID: https://orcid.org/0000-0002-1158-887X)
- Olga Kichakova
Institutions
- Sechenov University (RU)
- Research Institute of Fundamental and Clinical Immunology (RU)
- Genetic Resources Center (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1646404
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- I.M. Sechenov First Moscow State Medical University
- Ministry of Health of the Russian Federation